首页> 外文期刊>临床与转化肝病杂志(英文版) >Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis
【24h】

Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis

机译:基于抑制剂的病毒性肝炎治疗方法

获取原文
获取原文并翻译 | 示例
       

摘要

Viral hepatitis remains a significant worldwide threat,in spite of the availability of several successful therapeutic and vaccination strategies.Complications associated with acute and chronic infections,such as liver failure,cirrhosis and hepatocellular carcinoma,are the cause of considerable morbidity and mortality.Given the significant burden on the healthcare system caused by viral hepatitis,it is essential that novel,more effective therapeutics be developed.The present review attempts to summarize the current treatments against viral hepatitis,and provides an outline for upcoming,promising new therapeutics.Development of novel therapeutics requires an understanding of the viral life cycles and viral effectors in molecular detail.As such,this review also discusses virallyencoded effectors,found to be essential for virus survival and replication in the host milieu,which may be utilized as potential candidates for development of alternative therapies in the future.
机译:尽管有几种成功的治疗和疫苗接种策略,但病毒性肝炎仍然是世界范围内的重大威胁。与急性和慢性感染相关的并发症,例如肝功能衰竭,肝硬化和肝细胞癌,是造成相当高的发病率和死亡率的原因。由病毒性肝炎引起的医疗保健系统的巨大负担,开发新颖,更有效的治疗方法至关重要。本综述试图总结目前针对病毒性肝炎的治疗方法,并为即将到来的,有希望的新治疗方法提供概述。治疗药物需要详细了解病毒的生命周期和病毒效应子。因此,本综述还讨论了病毒编码的效应子,发现对于病毒在宿主环境中的存活和复制至关重要,这些效应子可以用作潜在的候选者。未来的替代疗法。

著录项

  • 来源
    《临床与转化肝病杂志(英文版)》 |2016年第3期|248-257|共10页
  • 作者

    Debajit Dey; Manidipa Banerjee;

  • 作者单位

    Kusuma School of Biological Sciences, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, India;

    Kusuma School of Biological Sciences, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, India;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号